Phase 2a clinical trial IPF
GRI Bio Won Orphan Drug Status the Same Day MAIA Opened a Third Cancer Trial Site
GRI Bio’s stock is down 94% over the past year. On June 18, the FDA handed it seven years of potential market exclusivity. The same day, across the industry, a different small-cap was quietly opening its third US trial site for a lung cancer drug nobody outside biotech circles has heard of. Regulatory wins and…
